Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer by Ueno, Tsuyoshi et al.
1 
 
Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor,  
on non-small cell lung cancer 
Tsuyoshi Uenoa, Kazunori Tsukudaa, Shinichi Toyookaa, Midori Andoa, 
Munenori Takaokab, Junichi Soha, Hiroaki Asanoa, Yuho Makia, Takayuki Muraokaa, 
Norimitsu Tanakaa, Kazuhiko Shiena, Masashi Furukawaa, Katsuyuki Kiurac, 
 Yoshio Naomotob and Shinichiro Miyoshia 
 
a Department of General Thoracic Surgery, Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, 
Okayama 700-8558, Japan 
b Department of General Surgery, Kawasaki Medical School, Okayama, Japan. 
c Department of Hematology, Oncology and Respiratory Medicine, Okayama 
University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
Okayama, Japan 
 
Key words: NSCLC, Hsp90, AUY922, EGFR, EGFR-TKI, mesothelioma 
 
Address correspondence to:  
Shinichi Toyooka 
Department of General Thoracic Surgery, Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences. 2-5-1 Shikata-cho, Kita-ku, Okayama 
700-8558, Japan  
TEL; +81-86-235-7265,  FAX; +81-86-235-7269 
E-mail; toyooka@md.okayama-u.ac.jp 
2 
 
ABSTRACT 
The anti-tumor activity of a newly developed Hsp90 inhibitor, NVP-AUY922 
(AUY922), against non-small cell lung cancer (NSCLC) was examined. Twenty-one 
NSCLC cell lines were used, the somatic alterations of which were characterized. Cell 
proliferation was analyzed using a modified MTS assay. Expression of the client 
proteins was assessed using Western blotting. The cell cycle was analyzed using flow 
cytometry. The IC50 value of AUY922 for the NSCLC cell lines ranged from 5.2 to 860 
nM (median, 20.4 nM). Based on previous data, cells with an IC50 of less than 50 nM 
were classified as sensitive cells and 19 of the 21 NSCLC cell lines were judged to be 
sensitive. The IC50 of five malignant pleural mesothelioma (MPM) cell lines revealed 
that the MPM cells had a significantly higher IC50 value (median, 89.2 nM; range, 
22.2-24,100 nM) than the NSCLC cells (p=0.015). There was significant depletion of 
both the total and phosphorylated client proteins - EGFR, MET, HER2 and AKT - at 
low drug concentrations (50-100 nM) in drug-sensitive cell lines. Cell-cycle analysis 
was performed for two sensitive cell lines, H1975 and H838. Following AUY922 
treatment, an increase in the sub-G0-G1 cell population, as well as appearance of cleaved 
PARP expression, indicated the induction of apoptosis. In conclusion, AUY922 was 
effective against most NSCLC cell lines, independent of the type of known molecular 
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alteration, and appears to be a promising new drug for the treatment of NSCLC. 
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1. Introduction 
Lung cancer is associated with various types of molecular alteration, including 
epidermal growth factor receptor (EGFR) mutation, K-ras mutation, HER2 
amplification and, as recently found, EMK4-ALK gene fusion.[1-3] Improvements in 
our understanding of the molecular alterations involved in lung cancer have brought 
significant advancements in molecular-targeted therapy.[4] Among these alterations, 
EGFR mutations, which are frequent alterations in lung adenocarcinoma, are a 
predictive factor for the efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs), 
such as gefitinib and erlotinib.[1, 2] These EGFR-TKIs have a marked anti-tumor effect 
on NSCLCs with common EGFR mutations. However, acquired resistance from, for 
example, a secondary EGFR T790M mutation or MET amplification is a major problem 
that is responsible for treatment failure.[5-7] 
 The heat-shock protein 90 (Hsp90) complex is a chaperone protein that 
facilitates the refolding of unfolded or misfolded proteins. It plays a pivotal role in 
cancer cell survival, as it stabilizes a large set of proteins, so-called client proteins, 
many of which are essential for apoptosis, cell-cycle regulation, proliferation, and other 
characteristic properties of cancer cells.[8, 9] In NSCLC, Hsp90 stabilizes oncogenic 
proteins such as EGFR, MET, HER2 and AKT.[9, 10] We and some other studies have 
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shown that geldanamycin (GM) and its analogues, the benzoquinone ansamycin class 
(17 allylamino-17demethoxygeldanamycin [17-AAG] and 17 dimethylaminoethylamino 
-17-demethoxygeldanamycin [17-DMAG]), are effective against EGFR-mutated cell 
lines, even those that contain the EGFR T790M mutation that causes resistance to 
EGFR-TKI.[11-14] However, the results of clinical trials for 17-AAG and 17-DMAG 
were somewhat disappointing [15-19] and new potent Hsp90 inhibitors have therefore 
been pharmacologically designed and synthesized to offer improved efficacy and 
acceptable toxicity. NVP-AUY922 (AUY922) is one of these newly designed 
small-molecule Hsp90 inhibitors based on the 4,5-diarylisoxazole scaffold; it has a 
much higher affinity for Hsp90 than previous GM analogues.[20] AUY922 is bound to 
the ATP binding site of Hsp90α at the N-terminal domain, and its X-ray crystal 
structure confirms a crucial network of hydrogen bonding interactions. It exhibits the 
tightest binding of any small-molecule Hsp90 ligand because the entropy of binding to 
Hsp90 is almost negligible. Indeed, preclinical data from various types of human cancer 
have shown an anti-proliferative effect of AUY922, with low nanomolar potency both 
in vivo and in vitro, with no major adverse effects being observed in mice.[20-24] In 
these studies, AUY922 suppressed the client proteins (EGFR, MET, HER2 and AKT) 
that participate in the progression of various cancer cells, and AUY922 is considered to 
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be a promising agent for NSCLC. However, to our knowledge, the efficacy of AUY992 
has been reported in only one NSCLC cell line (A549) to date,[25] although Phase II 
clinical trials for patients with advanced NSCLC have recently started.  
In this study, we examined the anti-tumor effect of AUY922 against NSCLC 
cell lines containing several known genetic alterations, including EGFR mutations. 
 
 
2. Materials and methods 
2.1. Drugs and cell lines 
 AUY922 was obtained from Novartis (Nuremberg, Germany) and dissolved in 
dimethyl sulfide (DMSO) at stocked concentrations of 10 mM and stored at -20°C. 
Working dilutions were always freshly prepared. Most of NSCLC and MPM cell lines 
used in this study were established at two institutions. The prefix NCI-H- (abbreviated 
as H-) indicates cell lines established at the National Cancer Institute-Navy Medical 
Oncology Branch, National Naval Medical Center, Bethesda, MD and the prefix HCC- 
indicates lines established at the Hamon Center for Therapeutic Oncology Research, the 
University of Texas Southwestern Medical Center at Dallas, Dallas, TX. These cell 
lines were kindly provided by Dr. Adi F. Gazdar (University of Texas Southwestern 
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Medical Center at Dallas, Dallas, TX, USA). A549 was purchased from American Type 
Culture Collection (Manassas, VA). NCI-H3255 was provided from Dr. Bruce Johnson 
(Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA). 
PC-9 was provided from Immuno-Biological Laboratories (Takasaki, Gunma, Japan). 
Gefitinib-resistant PC-9 cell line (RPC-9) were provided from the Department of 
Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate 
School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan.[26] All the cancer 
cell lines were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 
10% fetal bovine serum. All cell lines were incubated at 37°C in a humidified 
atmosphere with 5% CO2. 
 
2.2. Determination of cell proliferation   
 Cell proliferation was determined by a modified MTS assay with CellTiter 96® 
AQueous One Solution Reagent (Promega, Madison, WI). Cells were seeded on 96-well 
flat-bottomed tissue culture plates (Becton Dickinson, San Jose, CA) at a concentration 
of 3 × 103 cells/well with complete culture medium and allowed to adhere to the plate 
for 24 hours. Then the cells were incubated in the presence of the drug of each 
concentration ranging from 0 (control) to 10 μM of for another 72 hours at 37°C in a 
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humidified atmosphere of 5% CO2 in air. After the treatment, 20 μl of CellTiter 96® 
AQueous One Solution Reagent were dropped into each well of plates. After the 
incubation of another 60 minutes, the optical densities (OD) of these samples were 
directly measured using an Immuno Mini NJ-2300 (Nalge Nunc International, 
Rochester, NY). A reference wavelength at 490 nm was used to subtract background 
contributed by excess cell debris, fingerprints and other nonspecific absorbance. The 
OD of control samples was regarded as 100 and others were compared to the control. 
Each drug concentration was distributed in 4-replicate wells and each experiment was 
repeated thrice. The anti-proliferative activity of AUY922 was shown as IC50, which is 
the concentration of the drug required to inhibit cell proliferation by 50%. 
 
2.3. Western blot analysis and immunoprecipitation 
 Protein expression analysis was assessed by Western blotting. The lysate was 
extracted and 20 µg of total protein were then separated by SDS-PAGE and transferred 
to polyvinylidene fluoride (PVDF) membrane. The membranes were incubated with 
anti-EGFR, anti-phospho-EGFR (Ty1068), anti-Met (25H2), anti-phospho-Met (3D7, 
Tyr1234/1235), anti-HER2, anti-phospho-HER2 (Tyr877), anti-Akt, anti-phosphor-Akt 
(Ser473), anti-p44/42 mitrogen-activated protein kinases (MAPK), 
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anti-phosphor-MAPK (Thr202/Tyr204), anti-Cyclin D1, anti-cdc2 and anti-cleaved poly 
(ADP-ribose) polymerase (PARP) (Asp214) (19F4) antibodies (Cell Signaling 
Technology, Beverly, MA), anti-Hsp90 (Novocastra, Newcastle, UK), anti-Hsp70 
(Stressgen Bioreagents, Ann Arbor, MI), anti-CDK4 (C-22) (Santa Cruz Biotechnology, 
Santa Cruz, CA), anti-Actin (used as loading control, Millipore Billerica, MA) and then 
with goat anti-rabbit and goat anti-mouse IgG-HRP coupled to horseradish peroxidase 
conjugated secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). After the 
incubation with antibodies, the membranes were developed by ECL Plus Western 
Blotting Detection Reagents (Amersham Biosciences UK Limited, Buckinghamshire, 
UK). 
 
2.4. Flow cytometric analysis 
 Cells were harvested and resuspended in PBS containing 0.2% Triton X-100 
and 1 mg/mL RNase for 5 min at room temperature and then stained with propidium 
iodide at 50 μg/mL to determine subdiploid DNA content using a FACScan. Doublets, 
cell debris, and fixation artifacts were gated out, and cell cycle analysis was done using 
CellQuest version 3.3 software. 
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3. Results 
3.1. Anti-proliferative effect of AUY922 in NSCLC cell lines 
The concentrations of AUY922 at IC50 in each cell line are shown in Table I 
and Fig. 1. The molecular characteristics of NSCLC cell lines are also described (Table 
I). The IC50 values in the NSCLC cell lines ranged from 5.2 to 860 nM, whereas those 
in the MPM cell lines ranged from 22.2 to 24,100 nM (p=0.015), indicating a significant 
difference in AUY922 sensitivity between NSCLC and MPM cell lines. For NSCLC, 
AUY922 exhibited a strong anti-proliferative effect in cell lines with EGFR mutations 
that were either sensitive to EGFR-TKI or that had acquired resistance to EGFR-TKI, 
similar to the effects of GM analogues. Furthermore, AUY922 also exhibited 
anti-proliferative effects on cell lines with wild-type EGFR, a K-ras mutation, 
EML4-ALK fusion gene, or other genetic alterations. 
We also determined the IC50 value of the SKBR3 breast cancer cell line to 
validate the IC50 value determined with our MTS assay by comparing it with published 
data.[22] Our and previously published IC50 values were 9.7 + 3.5 nM and 3.3 + 0.9 nM, 
respectively, suggesting that the IC50 value measured using our system was not 
remarkably different from the published data.[22] Thus, in accordance with the 
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published criteria, an IC50 value of less than 50 nM was regarded as being a sensitive 
cell line.[22] On the basis of this criteria, 19 of the 21 NSCLC cell lines and two of the 
five MPM cell lines were classified as being sensitive (p=0.034). 
Two cell lines, H1395 and Calu3, were considered to be resistant. H1395 
contains a B-raf mutation as a known molecular alteration, while Calu3 has a strong 
amplification of HER2 and increased copy numbers of EGFR and PIK3CA. However, 
the H2170 cell line, which also exhibited strong HER2 amplification and an increased 
copy number of EGFR, was classified as a sensitive cell line (IC50 = 9.1 + 0.3), 
suggesting that amplification of HER2 or EGFR is not the factor that causes resistance 
to AUY922. 
 
3.2. Effects of AUY922 on molecular signature in NSCLC cell lines 
 Subsequent experiments focused on NSCLC. The effect of AUY922 on protein 
expression was examined according to concentration and exposure time in three 
sensitive cell lines (H1975, A549 and H838) and two resistant cell lines (H1395 and 
Calu3). Cells were harvested 24 hours after drug treatment in a concentration gradient 
experiment (Fig. 2 and Supplementary Fig. 1). In sensitive cell lines, the depletion of 
both the total and the phosphorylated client proteins, such as EGFR, MET, HER2, AKT, 
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and Cyclin D1 (CCND1), was observed after treatment with 50 nM of AUY922. 
Suppression of phospho-MAPK (p-MAPK) but not total-MAPK (t-MAPK) may be 
caused by down-regulation of its upstream molecules, which are the client proteins of 
Hsp90. Although inhibition of Hsp90 activity with drugs is generally correlated with 
Hsp70 protein levels after treatment,[22, 27] Hsp70 expression increased in both 
sensitive and resistant cell lines. In terms of the resistant cell lines, although expression 
of the client proteins was not depleted after treatment with a high concentration of 
AUY922 in Calu3 (IC50 = 248 nM), H1395-another resistant cell line (IC50 = 
850nM)-showed depletion of client proteins after treatment with AUY922 at a low 
concentration (Fig. 2 and Supplementary Fig. 1).  
For exposure time analysis, each cell line except H1395 was treated with the 
AUY922 concentration, which was five times as high as each IC50. H1395, the IC50 of 
which was 850 nM, was exposed to 100 nM of AUY922. Although variation of protein 
depletion and recovery was observed according to proteins or cell lines, decreased 
expression of the majority of proteins was observed from 12 to 72 hours (Fig. 3 and 
Supplementary Fig. 2). Of note, there was no major difference in the pattern of the 
protein expression profile time course between sensitive cell lines and H1395-resistant 
cell lines. 
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3.3. Effects of AUY922 on cell cycle and apoptosis 
We analyzed the cell cycle in two sensitive cell lines (H1975 and H838) to 
examine the impact of AUY922 on cell-cycle distribution, especially induction of 
apoptosis. Whereas the pattern of cell-cycle distribution after treatment of AUY922 was 
different between two cell lines, sub-G0-G1 DNA content increased in a time-dependent 
manner for both cell lines. Cleaved PARP also increased with AUY922 treatment, 
indicating that AUY922 induced apoptosis in these two cell lines (Fig. 4). 
 
 
4. Discussion 
In this study, we found that AUY922 had a strong anti-proliferative effect on 
most NSCLC cell lines. Previous studies have indicated that GM analogue Hsp90 
inhibitors have an anti-tumor effect on EGFR mutant NSCLC cell lines, including 
acquired TKI-resistant NSCLC. This suggests that Hsp90 inhibitors are promising 
agents for resistance to EGFR-TKI in the treatment of NSCLC.[12] However, a recent 
clinical trial for IPI-504, an analog of 17-AAG, failed to show its significant 
effectiveness for EGFR mutant NSCLC patients.[17] On the other hand, IPI-504 
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showed response to 2 of 3 NSCLC patients with EML4-ALK fusion gene. One of the 
reasons is that enrolled patients with EGFR mutation had been treated at least two prior 
EGFR-TKI agents, suggesting that the biological features of these EGFR mutant tumors 
might be different from those of untreated tumors with single oncogene addicted status. 
In addition, cancer cell lines with EML4-ALK might be more sensitive for 17-AAG than 
those with EGFR mutation.[17] Unlike GM analogues including 17-AAG, AUY992 
exhibited similar anti-tumor effect not only in EGFR mutant tumors, but also in 
wild-type EGFR tumors with various molecular alterations including K-ras mutation, 
EML4-ALK fusion gene, or MET or HER2 amplification. One reason is that AUY922 
has a much higher affinity for the N-terminal nucleotide-binding site of human Hsp90 
than other Hsp90 inhibitors and can strongly suppress the expression of many client 
proteins at low concentrations.[20] 
Cell-cycle distribution was examined in two cell lines to assess the induction of 
apoptosis, but the pattern of distributions was not identical. Many client proteins of 
Hsp90 are thought to be involved in the pathogenesis of cancers. The degree and 
manner of involvement of each client protein should vary according to the cancer type, 
resulting in variation of the cellular response, such as cell-cycle distribution and degree 
of apoptosis. This would account for the difference in pattern of cell distribution and 
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degree of apoptosis even in the sensitive cell lines. 
In our series, the two cell lines Calu3 and H1395 were regarded as being 
resistant to AUY922. The client proteins in Calu3 were not depleted with AUY922 
treatment as much. The fact that expression of Hsp70 was induced in Calu3 confirmed 
the inhibition of Hsp90 with AUY922, which suggested that drug transporters or 
metabolic activity might not be responsible for the resistance of Calu3. The cause of 
preserved expression of client proteins is unclear. In contrast, H1395 showed decreased 
expression of the client proteins at a low concentration of AUY922, which was similar 
to the response in sensitive cell lines. As early recovery of client proteins under 
AUY922 treatment was related to drug resistance in glioblastoma,[28] we examined 
whether there was a difference in the recovery time of depleted proteins between 
sensitive and resistant cell lines. However, there was no difference between them in 
NSCLC and the mechanism of resistance was unclear. One possible explanation for the 
observed resistance is that although Hsp90 has many client proteins that are generally 
essential for tumor proliferation and survival in the majority of cancers, when cancer 
cells do not depend on these client proteins for survival, the inhibition of Hsp90 may 
not be effective. Of clinical relevance, this point may suggest that the selection of 
patients suited to AUY922 treatment based on molecular properties is difficult. Further 
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investigation to identify the factors that can predict sensitivity or resistance to AUY922 
is necessary.  
Our results suggest that AUY922 is not effective in MPM compared to NSCLC. 
Although the precise mechanism of resistance is not clear, the molecular characteristics 
of MPM are different to those of NSCLC.[29, 30] Regarding the clinical use of 
AUY922, Phase I/II trials of intravenously administered AUY922 are currently ongoing 
(http://clinicaltrials.gov/) for patients with various types of cancer. From February 2011 
to present, two interesting clinical trials have begun for advanced NSCLC. The 
NCT01124864 trial is for patients who have received at least two lines of prior 
chemotherapy, and the patients are stratified according to K-ras and EGFR mutation 
status. The NCT01259089 trial is for patients with lung adenocarcinoma with "acquired 
resistance" to EGFR-TKI. It is noteworthy that our data strongly support the use of 
AUY922 for the treatment of NSCLC patients with various somatic alterations or with 
acquired resistance to EGFR-TKI. 
 In conclusion, our study suggests that AUY922 is a potent candidate for the 
treatment of the majority of NSCLCs, independent of the major known genetic 
alterations.  
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Table I. IC50 inhibition values for NVP-AUY922 in NSCLC and MPM cell lines 
              
Cancer 
type 
Cell lines 
Histological 
subtypes 
AUY922 
Genetic alterations 
*Sensitivity IC50 (nM) 
NSCLC PC-9 AD Sensitive 8.6 ± 0.5 
EGFR 
mutation 
Exon19 del. 
HCC2935 AD Sensitive 9.2 ± 0.1 Exon19 del. 
HCC827 AD Sensitive 16.9 ± 0.4 Exon19 del. 
HCC2279 AD Sensitive 26.3 ± 3.6 Exon19 del. 
HCC4011 AD Sensitive 17.9 ± 0.1 L858R 
H3255 AD Sensitive 29.5 ± 5.8 L858R 
RPC-9 AD Sensitive 20.4 ± 1.4 Exon19 del. + T790M 
H1975 AD Sensitive 5.2 ± 0.3 L858R + T790M 
H1650 AD Sensitive 23.5 ± 2.9 Exon19 del. + PTEN del.
H1299 LC Sensitive 32.4 ± 0.1 N-ras mutation 
A549 AD Sensitive 16.3 ± 0.6 K-ras mutation  
K-ras mutation 
K-ras mutation 
H2009 AD Sensitive 21.4 ± 0.8 
H358 AD Sensitive 28.1 ± 4.1 
H2170 SQ Sensitive 9.1 ± 0.3 HER2 amplification 
HER2 amplification 
HER2 amplification 
HER2 amplification 
H1648 AD Sensitive 9.6 ± 0.1 
H1819 AD Sensitive 23.9 ± 1.0 
Calu3 AD Resistant 248 ± 8.5 
H1993 AD Sensitive 7.7 ± 0.2 MET amplification 
H1395 AD Resistant 860 ± 7.1 B-raf mutation 
H2228 AD Sensitive 20.4 ± 6.5 
EML4-ALK fusion gene 
variant E6a/b;A20 
H838 AD Sensitive 17.1 ± 0.6 None 
      
MPM H211 Biphasic Sensitive 22.2 ± 3.8 
  
H290 Epithelial Sensitive 27.3 ± 3.8  
H28 Sarcomatoid Resistant 89.2 ± 8.2 
HP1 Biphasic Resistant 1,070 ± 10 
H2052 Epithelial Resistant 24,100 ± 4,900 
       
BC SKBR3   Sensitive 9.7 ± 3.5     
26 
 
NSCLC, non-small cell lung cancer: MPM, malignant pleural mesothelioma; BC, breast 
cancer; AD, adenocarcinoma; LC, large cell carcinoma; SQ, squamous cell carcinoma. 
*Sensitivity: sensitive cell lines, IC50 value < 50 nM; resistant cell lines, IC50 value > 50 
nM; del, deletion; NVP-AUY922 exhibited strong effects to most NSCLC cell lines 
with EGFR and K-ras mutation or HER2 and MET amplification.  
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FIGURE LEGENDS 
Fig. 1. IC50 values of non-small cell lung cancer and malignant pleural mesothelioma 
cell lines. 
 
Fig. 2. The profiles of protein expression under the treatment of different AUY922 
concentration for 24 hours.   
 
Fig. 3. The profiles of protein expression according to exposure time with AUY922.  
Each NSCLC cell line (H1975, A549, and H838) was treated with AUY922 of which 
concentration was five times as high as each IC50. H1395 was exposed to 100 nM of 
AUY922. 
 
Fig. 4. The impact of AUY922 on cell cycle distribution and induction of apoptosis. 
Using two sensitive cell lines, cell cycle distribution was analyzed using flow cytometry 
and cleaved PARP expression was examined using Western blotting. After treatment of 
AUY922, sub-G0-G1 DNA content increased in a time-dependent manner and cleaved 
PARP also increased with AUY922 treatment. 
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Supplementary Fig. 1. The profiles of phospho-protein expression under the treatment 
of different AUY922 concentration for 24 hours. 
 
Supplementary Fig. 2. The profiles of phospho-protein expression according to 
exposure time with AUY922. Each NSCLC cell line (H1975, A549, and H838) was 
treated with AUY922 of which concentration was five times as high as each IC50. 
H1395 was exposed to 100 nM of AUY922. 
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